Outcomes in COVID-19 molnupiravir studies
Outcomes in molnupiravir studies.
Potential risks include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity Chamod , Gruber , Hadj Hassine , Huntsman , Marikawa , Shiraki , Shum , Standing , Swanstrom , Waters , Zhou , Zibat Multiple analyses have identified variants potentially created by molnupiravir
Focosi , Fountain-Jones , Kosakovsky Pond , Sanderson , twitter.com . There is substantial publication bias. Multiple trials have not reported results and did not respond to requests
Lawrence .
0
0.5
1
1.5+ All studies 11% 46 151,398 Improvement, Studies, Patients Relative Risk Mortality 15% 24 124,940 Ventilation 20% 8 24,515 ICU admission 6% 7 28,430 Hospitalization 2% 20 79,514 Progression 32% 6 33,432 Recovery 12% 11 28,091 Cases 24% 1 1,527 Viral clearance 25% 13 9,337 RCTs 23% 17 31,458 RCT mortality -1% 5 25,832 Peer-reviewed 14% 34 122,324 Prophylaxis 24% 1 1,527 Early 12% 36 94,682 Late 11% 9 55,189 Molnupiravir for COVID-19 c19 earlyDecember 2024 after exclusions Favors molnupiravir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 52% 0.48 [0.40-0.59] death 1,856 (n) 1,856 (n) Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Zou (RCT) 29% 0.71 [0.28-1.85] recov. time 77 (n) 31 (n) Flisiak 39% 0.61 [0.38-0.97] death 20/203 63/387 AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 Kneidinger -15% 1.15 [0.56-2.37] severe case 8/46 26/172 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] death 22/2,661 27/2,661 Arbel 65+ 74% 0.26 [0.10-0.73] death 4/845 137/12,724 Arbel 40-64 -1182% 12.82 [3.41-48.2] death 4/224 7/6,075 Suzuki (PSM) -100% 2.00 [0.34-11.9] death 2/230 3/690 Brown -101% 2.01 [0.43-9.38] hosp. 8/442 2/222 PANORAMIC Butler (RCT) -27% 1.27 [0.65-2.48] death 20/11,778 15/11,230 Wong (PSM) 24% 0.76 [0.61-0.95] death Liu -162% 2.62 [0.11-60.6] ICU 1/26 0/16 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Zheng -100% 2.00 [1.23-3.23] death/hosp. 61/2,689 34/3,331 OT1 Bajema (PSM) 18% 0.82 [0.52-1.29] death 24/897 29.0/897 Inaba 58% 0.42 [0.02-10.1] death 0/84 1/210 Zheng (PSW) -285% 3.85 [1.54-10.0] death/hosp. 11/802 33/4,836 OT1 Evans 51% 0.49 [0.29-0.83] death/hosp. 359 (n) 4,973 (n) Goodwin -110% 2.10 [0.19-22.9] death 1/80 2/336 Tazare -9% 1.09 [0.93-1.27] death/hosp. Butt -9% 1.09 [0.73-1.63] death/hosp. 48/1,459 44/1,459 Fung 4% 0.96 [0.93-0.99] PASC population-based cohort LONG COVID DAWN Tare (RCT) -83% 1.83 [0.69-4.82] no recov. 4/7 5/16 Cheng 15% 0.85 [0.77-0.95] death 4,146 (n) 5,792 (n) Standing (RCT) -103% 2.03 [0.52-7.94] viral+ 6/117 3/119 Razia -272% 3.72 [0.35-39.4] death 2/29 1/54 Yen 18% 0.82 [0.50-1.33] death 250 (n) 1,946 (n) SAVALO Gentile (PSM) 4% 0.96 [0.70-1.31] death case control Tau2 = 0.08, I2 = 80.5%, p = 0.072 Early treatment 12% 0.88 [0.76-1.01] 316/32,022 601.0/62,660 12% lower risk 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING2 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING2 MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Wan 11% 0.89 [0.81-0.98] death 704/6,153 2,541/17,283 Wan 13% 0.87 [0.81-0.93] death 2,700 (n) 13,795 (n) Özdemir -50% 1.50 [0.27-8.49] death 3/39 2/39 RECOVERY Horby (RCT) -11% 1.11 [0.79-1.58] death 57/445 55/478 Lv -53% 1.53 [0.83-2.83] death 12/67 30/257 Lai 10% 0.90 [0.83-0.97] death 4,975 (n) 8,667 (n) Tau2 = 0.00, I2 = 0.0%, p < 0.0001 Late treatment 11% 0.89 [0.85-0.93] 787/14,595 2,629/40,594 11% lower risk MOVe-AHEAD Alpizar (DB RCT) 24% 0.76 [0.57-1.01] symp. case 78/763 103/764 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.049 Prophylaxis 24% 0.76 [0.57-1.01] 78/763 103/764 24% lower risk All studies 11% 0.89 [0.81-0.97] 1,181/47,380 3,333.0/104,018 11% lower risk 46 molnupiravir COVID-19 studies c19 earlyDecember 2024 Tau2 = 0.03, I2 = 76.8%, p = 0.0068 Effect extraction pre-specified 1 OT: comparison with other treatment 2 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 52% 0.48 [0.40-0.59] death 1,856 (n) 1,856 (n) Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Zou (RCT) 29% 0.71 [0.28-1.85] recov. time 77 (n) 31 (n) Flisiak 39% 0.61 [0.38-0.97] death 20/203 63/387 AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 Kneidinger -15% 1.15 [0.56-2.37] severe case 8/46 26/172 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] death 22/2,661 27/2,661 Arbel 65+ 74% 0.26 [0.10-0.73] death 4/845 137/12,724 Arbel 40-64 -1182% 12.82 [3.41-48.2] death 4/224 7/6,075 Suzuki (PSM) -100% 2.00 [0.34-11.9] death 2/230 3/690 PANORAMIC Butler (RCT) -27% 1.27 [0.65-2.48] death 20/11,778 15/11,230 Wong (PSM) 24% 0.76 [0.61-0.95] death Liu -162% 2.62 [0.11-60.6] ICU 1/26 0/16 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Zheng -100% 2.00 [1.23-3.23] death/hosp. 61/2,689 34/3,331 OT1 Bajema (PSM) 18% 0.82 [0.52-1.29] death 24/897 29.0/897 Inaba 58% 0.42 [0.02-10.1] death 0/84 1/210 Evans 51% 0.49 [0.29-0.83] death/hosp. 359 (n) 4,973 (n) Goodwin -110% 2.10 [0.19-22.9] death 1/80 2/336 Tazare -9% 1.09 [0.93-1.27] death/hosp. Butt -9% 1.09 [0.73-1.63] death/hosp. 48/1,459 44/1,459 Fung 4% 0.96 [0.93-0.99] PASC population-based cohort LONG COVID DAWN Tare (RCT) -83% 1.83 [0.69-4.82] no recov. 4/7 5/16 Cheng 15% 0.85 [0.77-0.95] death 4,146 (n) 5,792 (n) Standing (RCT) -103% 2.03 [0.52-7.94] viral+ 6/117 3/119 Razia -272% 3.72 [0.35-39.4] death 2/29 1/54 Yen 18% 0.82 [0.50-1.33] death 250 (n) 1,946 (n) SAVALO Gentile (PSM) 4% 0.96 [0.70-1.31] death case control Tau2 = 0.07, I2 = 79.6%, p = 0.012 Early treatment 16% 0.84 [0.73-0.96] 297/30,778 566.0/57,602 16% lower risk 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING2 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING2 MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Wan 11% 0.89 [0.81-0.98] death 704/6,153 2,541/17,283 Wan 13% 0.87 [0.81-0.93] death 2,700 (n) 13,795 (n) Özdemir -50% 1.50 [0.27-8.49] death 3/39 2/39 RECOVERY Horby (RCT) -11% 1.11 [0.79-1.58] death 57/445 55/478 Lv -53% 1.53 [0.83-2.83] death 12/67 30/257 Lai 10% 0.90 [0.83-0.97] death 4,975 (n) 8,667 (n) Tau2 = 0.00, I2 = 0.0%, p < 0.0001 Late treatment 11% 0.89 [0.85-0.93] 787/14,595 2,629/40,594 11% lower risk MOVe-AHEAD Alpizar (DB RCT) 24% 0.76 [0.57-1.01] symp. case 78/763 103/764 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.049 Prophylaxis 24% 0.76 [0.57-1.01] 78/763 103/764 24% lower risk All studies 14% 0.86 [0.79-0.94] 1,162/46,136 3,298.0/98,960 14% lower risk 44 molnupiravir COVID-19 studies after exclusions c19 earlyDecember 2024 Tau2 = 0.03, I2 = 75.6%, p = 0.00098 Effect extraction pre-specified 1 OT: comparison with other treatment 2 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Fischer (RCT) 77% 0.23 [0.01-5.69] 0/140 1/62 Improvement, RR [CI] Treatment Control MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] 1/709 9/699 Wong (PSM) 52% 0.48 [0.40-0.59] 1,856 (n) 1,856 (n) Flisiak 39% 0.61 [0.38-0.97] 20/203 63/387 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] 22/2,661 27/2,661 Arbel 65+ 74% 0.26 [0.10-0.73] 4/845 137/12,724 Arbel 40-64 -1182% 12.82 [3.41-48.2] 4/224 7/6,075 Suzuki (PSM) -100% 2.00 [0.34-11.9] 2/230 3/690 PANORAMIC Butler (RCT) -27% 1.27 [0.65-2.48] 20/11,778 15/11,230 Wong (PSM) 24% 0.76 [0.61-0.95] Bajema (PSM) 18% 0.82 [0.52-1.29] 24/897 29.0/897 Inaba 58% 0.42 [0.02-10.1] 0/84 1/210 Goodwin -110% 2.10 [0.19-22.9] 1/80 2/336 Cheng 15% 0.85 [0.77-0.95] 4,146 (n) 5,792 (n) Razia -272% 3.72 [0.35-39.4] 2/29 1/54 Yen 18% 0.82 [0.50-1.33] 250 (n) 1,946 (n) SAVALO Gentile (PSM) 4% 0.96 [0.70-1.31] case control Tau2 = 0.11, I2 = 75.2%, p = 0.08 Early treatment 19% 0.81 [0.64-1.03] 100/24,132 295.0/45,619 19% lower risk MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] 11/216 1/75 Improvement, RR [CI] Treatment Control Wan 11% 0.89 [0.81-0.98] 704/6,153 2,541/17,283 Wan 13% 0.87 [0.81-0.93] 2,700 (n) 13,795 (n) Özdemir -50% 1.50 [0.27-8.49] 3/39 2/39 RECOVERY Horby (RCT) -11% 1.11 [0.79-1.58] 57/445 55/478 Lv -53% 1.53 [0.83-2.83] 12/67 30/257 Lai 10% 0.90 [0.83-0.97] 4,975 (n) 8,667 (n) Tau2 = 0.00, I2 = 18.8%, p < 0.0001 Late treatment 11% 0.89 [0.85-0.95] 787/14,595 2,629/40,594 11% lower risk All studies 15% 0.85 [0.76-0.95] 887/38,727 2,924.0/86,213 15% lower risk 24 molnupiravir COVID-19 mortality results c19 earlyDecember 2024 Tau2 = 0.03, I2 = 71.8%, p = 0.0049 Favors molnupiravir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Wong (PSM) 58% 0.42 [0.17-1.01] 1,856 (n) 1,856 (n) Improvement, RR [CI] Treatment Control Flisiak 5% 0.95 [0.39-2.32] 7/203 14/387 Suzuki (PSM) 57% 0.43 [0.02-10.5] 0/230 1/690 Wong (PSM) 60% 0.40 [0.19-0.84] Bajema (PSM) 17% 0.83 [0.17-4.12] 3/897 3.6/897 Razia -86% 1.86 [0.12-28.7] 1/29 1/54 Tau2 = 0.00, I2 = 0.0%, p = 0.011 Early treatment 44% 0.56 [0.36-0.88] 11/3,215 19.6/3,884 44% lower risk Wan -7% 1.07 [0.89-1.30] 2,700 (n) 13,795 (n) Improvement, RR [CI] Treatment Control RECOVERY Horby (RCT) -43% 1.43 [0.50-4.08] 8/445 6/476 Tau2 = 0.00, I2 = 0.0%, p = 0.43 Late treatment -8% 1.08 [0.90-1.30] 8/3,145 6/14,271 8% higher risk All studies 20% 0.80 [0.54-1.19] 19/6,360 25.6/18,155 20% lower risk 8 molnupiravir COVID-19 mechanical ventilation results c19 earlyDecember 2024 Tau2 = 0.10, I2 = 35.4%, p = 0.27 Favors molnupiravir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Wong (PSM) 26% 0.74 [0.45-1.21] Improvement, RR [CI] Treatment Control Liu -162% 2.62 [0.11-60.6] 1/26 0/16 Bajema (PSM) 1% 0.99 [0.41-2.37] 10/897 10.1/897 Cheng 12% 0.88 [0.59-1.30] 4,146 (n) 5,792 (n) Razia -86% 1.86 [0.28-12.5] 2/29 2/54 Tau2 = 0.00, I2 = 0.0%, p = 0.31 Early treatment 14% 0.86 [0.65-1.15] 13/5,098 12.1/6,759 14% lower risk Wan -2% 1.02 [0.76-1.36] 2,700 (n) 13,795 (n) Improvement, RR [CI] Treatment Control Özdemir 0% 1.00 [0.15-6.75] 2/39 2/39 Tau2 = 0.00, I2 = 0.0%, p = 0.9 Late treatment -2% 1.02 [0.76-1.36] 2/2,739 2/13,834 2% higher risk All studies 6% 0.94 [0.76-1.15] 15/7,837 14.1/20,593 6% lower risk 7 molnupiravir COVID-19 ICU results c19 earlyDecember 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.54 Favors molnupiravir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Fischer (RCT) -33% 1.33 [0.14-12.5] hosp. 3/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 6% 0.94 [0.89-1.00] hosp. time 1,856 (n) 1,856 (n) Yip (PSW) -17% 1.17 [0.99-1.39] hosp. Flisiak -1% 1.01 [0.71-1.43] hosp. time 203 (n) 387 (n) AGILE CST-2 Khoo (DB RCT) 89% 0.11 [0.01-2.03] hosp. 0/90 4/90 Arbel 65+ 45% 0.55 [0.34-0.88] hosp. 18/845 513/12,724 Arbel 40-64 -80% 1.80 [0.86-3.77] hosp. 8/224 97/6,075 Brown -101% 2.01 [0.43-9.38] hosp. 8/442 2/222 PANORAMIC Butler (RCT) -7% 1.07 [0.81-1.41] hosp. 103/12,529 96/12,525 Wong (PSM) 2% 0.98 [0.89-1.06] hosp. Liu 18% 0.82 [0.63-1.06] hosp. time 26 (n) 16 (n) Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Bajema (PSM) -30% 1.30 [1.01-1.68] hosp. 162/897 124.3/897 Inaba -127% 2.27 [0.60-7.25] hosp. 5/84 8/210 Goodwin 58% 0.42 [0.05-3.23] hosp. 1/80 10/336 Razia 28% 0.72 [0.28-1.81] hosp. 5/29 13/54 SAVALO Gentile (PSM) 26% 0.74 [0.13-4.18] hosp. case control Tau2 = 0.02, I2 = 66.5%, p = 0.54 Early treatment 4% 0.96 [0.86-1.08] 336/19,034 930.3/37,044 4% lower risk Wan 1% 0.99 [0.93-1.05] hosp. 2,298/6,153 2,541/17,283 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.7 Late treatment 1% 0.99 [0.93-1.05] 2,298/6,153 2,541/17,283 1% lower risk All studies 2% 0.98 [0.90-1.07] 2,634/25,187 3,471.3/54,327 2% lower risk 20 molnupiravir COVID-19 hospitalization results c19 earlyDecember 2024 Tau2 = 0.01, I2 = 64.7%, p = 0.68 Favors molnupiravir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 52% 0.48 [0.40-0.59] death 1,856 (n) 1,856 (n) Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Flisiak 39% 0.61 [0.38-0.97] death 20/203 63/387 AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 Kneidinger -15% 1.15 [0.56-2.37] severe case 8/46 26/172 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] death 22/2,661 27/2,661 Arbel 65+ 74% 0.26 [0.10-0.73] death 4/845 137/12,724 Arbel 40-64 -1182% 12.82 [3.41-48.2] death 4/224 7/6,075 Suzuki (PSM) -100% 2.00 [0.34-11.9] death 2/230 3/690 Brown -101% 2.01 [0.43-9.38] hosp. 8/442 2/222 PANORAMIC Butler (RCT) -27% 1.27 [0.65-2.48] death 20/11,778 15/11,230 Wong (PSM) 24% 0.76 [0.61-0.95] death Liu -162% 2.62 [0.11-60.6] ICU 1/26 0/16 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Zheng -100% 2.00 [1.23-3.23] death/hosp. 61/2,689 34/3,331 OT1 Bajema (PSM) 18% 0.82 [0.52-1.29] death 24/897 29.0/897 Inaba 58% 0.42 [0.02-10.1] death 0/84 1/210 Zheng (PSW) -285% 3.85 [1.54-10.0] death/hosp. 11/802 33/4,836 OT1 Evans 51% 0.49 [0.29-0.83] death/hosp. 359 (n) 4,973 (n) Goodwin -110% 2.10 [0.19-22.9] death 1/80 2/336 Tazare -9% 1.09 [0.93-1.27] death/hosp. Butt -9% 1.09 [0.73-1.63] death/hosp. 48/1,459 44/1,459 Fung 4% 0.96 [0.93-0.99] PASC population-based cohort LONG COVID Cheng 15% 0.85 [0.77-0.95] death 4,146 (n) 5,792 (n) Razia -272% 3.72 [0.35-39.4] death 2/29 1/54 Yen 18% 0.82 [0.50-1.33] death 250 (n) 1,946 (n) SAVALO Gentile (PSM) 4% 0.96 [0.70-1.31] death case control Tau2 = 0.07, I2 = 80.0%, p = 0.12 Early treatment 11% 0.89 [0.77-1.03] 260/31,634 497.0/62,308 11% lower risk MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Improvement, RR [CI] Treatment Control Wan 11% 0.89 [0.81-0.98] death 704/6,153 2,541/17,283 Wan 13% 0.87 [0.81-0.93] death 2,700 (n) 13,795 (n) Özdemir -50% 1.50 [0.27-8.49] death 3/39 2/39 RECOVERY Horby (RCT) -11% 1.11 [0.79-1.58] death 57/445 55/478 Lv -53% 1.53 [0.83-2.83] death 12/67 30/257 Lai 10% 0.90 [0.83-0.97] death 4,975 (n) 8,667 (n) Tau2 = 0.00, I2 = 18.8%, p < 0.0001 Late treatment 11% 0.89 [0.85-0.95] 787/14,595 2,629/40,594 11% lower risk All studies 10% 0.90 [0.83-0.99] 1,047/46,229 3,126.0/102,902 10% lower risk 38 molnupiravir COVID-19 serious outcomes c19 earlyDecember 2024 Tau2 = 0.03, I2 = 77.3%, p = 0.03 Effect extraction pre-specified (most serious outcome) 1 OT: comparison with other treatment Favors molnupiravir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Hetero (RCT) 33% 0.67 [0.54-0.82] recov. time 371 (n) 370 (n) Improvement, RR [CI] Treatment Control Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 MOVe-OUT Jayk Ber.. (DB RCT) 15% 0.85 [0.75-0.98] recovery 709 (n) 699 (n) Zou (RCT) 29% 0.71 [0.28-1.85] recov. time 77 (n) 31 (n) AGILE CST-2 Khoo (DB RCT) -12% 1.12 [0.71-1.79] no recov. 27/90 24/90 PANORAMIC Butler (RCT) 22% 0.78 [0.75-0.81] no recov. 3,856/12,403 4,838/12,140 DAWN Tare (RCT) -83% 1.83 [0.69-4.82] no recov. 4/7 5/16 Tau2 = 0.01, I2 = 44.4%, p = 0.00027 Early treatment 19% 0.81 [0.72-0.91] 3,895/13,669 4,870/13,352 19% lower risk 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING1 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING1 MOVe-IN Arribas (DB RCT) 1% 0.99 [0.68-1.45] no recov. 72 (n) 75 (n) RECOVERY Horby (RCT) -9% 1.09 [0.88-1.35] no disch. 126/445 124/478 Tau2 = 0.00, I2 = 0.0%, p = 0.53 Late treatment -6% 1.06 [0.89-1.26] 126/517 124/553 6% higher risk All studies 12% 0.88 [0.78-0.99] 4,021/14,186 4,994/13,905 12% lower risk 11 molnupiravir COVID-19 recovery results c19 earlyDecember 2024 Tau2 = 0.01, I2 = 55.0%, p = 0.031 1 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ MOVe-AHEAD Alpizar (DB RCT) 24% 0.76 [0.57-1.01] symp. case 78/763 103/764 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.049 Prophylaxis 24% 0.76 [0.57-1.01] 78/763 103/764 24% lower risk All studies 24% 0.76 [0.57-1.01] 78/763 103/764 24% lower risk 1 molnupiravir COVID-19 case result c19 earlyDecember 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.049 Favors molnupiravir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Fischer (RCT) 49% 0.51 [0.22-1.18] viral+ 10/118 9/54 Improvement, RR [CI] Treatment Control Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 MOVe-OUT Jayk Ber.. (DB RCT) 4% 0.96 [0.90-1.02] viral load 518 (n) 510 (n) Tippabhotla (RCT) 59% 0.41 [0.29-0.57] viral+ 42/610 103/610 Wong (PSM) 28% 0.72 [0.61-0.87] viral+ 1,856 (n) 1,856 (n) Zou (RCT) 10% 0.90 [0.83-0.97] viral time 76 (n) 31 (n) AGILE CST-2 Khoo (DB RCT) 23% 0.77 [0.58-1.09] viral+ 90 (n) 90 (n) PANORAMIC Butler (RCT) -95% 1.95 [1.15-3.31] viral load 21 (n) 11 (n) Liu 21% 0.79 [0.59-1.05] viral time 26 (n) 16 (n) Sinha (RCT) 48% 0.52 [0.42-0.63] viral load 608 (n) 610 (n) Standing (RCT) -103% 2.03 [0.52-7.94] viral+ 6/117 3/119 Tau2 = 0.06, I2 = 89.2%, p = 0.0006 Early treatment 27% 0.73 [0.60-0.87] 96/4,215 208/4,087 27% lower risk MOVe-IN Arribas (DB RCT) 12% 0.88 [0.62-1.25] viral+ 26/52 34/60 Improvement, RR [CI] Treatment Control RECOVERY Horby (RCT) 12% 0.88 [0.85-0.91] viral load 445 (n) 478 (n) Tau2 = 0.00, I2 = 0.0%, p < 0.0001 Late treatment 12% 0.88 [0.85-0.91] 26/497 34/538 12% lower risk All studies 25% 0.75 [0.67-0.85] 122/4,712 242/4,625 25% lower risk 13 molnupiravir COVID-19 viral clearance results c19 earlyDecember 2024 Tau2 = 0.03, I2 = 87.1%, p < 0.0001 Favors molnupiravir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Zou (RCT) 29% 0.71 [0.28-1.85] recov. time 77 (n) 31 (n) AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 PANORAMIC Butler (RCT) -27% 1.27 [0.65-2.48] death 20/11,778 15/11,230 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 DAWN Tare (RCT) -83% 1.83 [0.69-4.82] no recov. 4/7 5/16 Standing (RCT) -103% 2.03 [0.52-7.94] viral+ 6/117 3/119 Tau2 = 0.29, I2 = 61.3%, p = 0.052 Early treatment 35% 0.65 [0.42-1.00] 100/14,694 192/14,023 35% lower risk 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING1 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING1 MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 RECOVERY Horby (RCT) -11% 1.11 [0.79-1.58] death 57/445 55/478 Tau2 = 0.00, I2 = 0.0%, p = 0.51 Late treatment -10% 1.10 [0.83-1.46] 68/661 56/553 10% higher risk MOVe-AHEAD Alpizar (DB RCT) 24% 0.76 [0.57-1.01] symp. case 78/763 103/764 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.049 Prophylaxis 24% 0.76 [0.57-1.01] 78/763 103/764 24% lower risk All studies 23% 0.77 [0.57-1.04] 246/16,118 351/15,340 23% lower risk 17 molnupiravir COVID-19 Randomized Controlled Trials c19 earlyDecember 2024 Tau2 = 0.19, I2 = 63.7%, p = 0.087 Effect extraction pre-specified 1 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Fischer (RCT) 77% 0.23 [0.01-5.69] 0/140 1/62 Improvement, RR [CI] Treatment Control MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] 1/709 9/699 PANORAMIC Butler (RCT) -27% 1.27 [0.65-2.48] 20/11,778 15/11,230 Tau2 = 1.60, I2 = 64.8%, p = 0.36 Early treatment 58% 0.42 [0.07-2.56] 21/12,627 25/11,991 58% lower risk MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] 11/216 1/75 Improvement, RR [CI] Treatment Control RECOVERY Horby (RCT) -11% 1.11 [0.79-1.58] 57/445 55/478 Tau2 = 0.21, I2 = 27.3%, p = 0.51 Late treatment -35% 1.35 [0.56-3.26] 68/661 56/553 35% higher risk All studies -1% 1.01 [0.54-1.91] 89/13,288 81/12,544 1% higher risk 5 molnupiravir COVID-19 RCT mortality results c19 earlyDecember 2024 Tau2 = 0.19, I2 = 45.4%, p = 0.98 Favors molnupiravir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Improvement, RR [CI] Treatment Control Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 52% 0.48 [0.40-0.59] death 1,856 (n) 1,856 (n) Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Zou (RCT) 29% 0.71 [0.28-1.85] recov. time 77 (n) 31 (n) Flisiak 39% 0.61 [0.38-0.97] death 20/203 63/387 AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 Kneidinger -15% 1.15 [0.56-2.37] severe case 8/46 26/172 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] death 22/2,661 27/2,661 Suzuki (PSM) -100% 2.00 [0.34-11.9] death 2/230 3/690 Brown -101% 2.01 [0.43-9.38] hosp. 8/442 2/222 PANORAMIC Butler (RCT) -27% 1.27 [0.65-2.48] death 20/11,778 15/11,230 Wong (PSM) 24% 0.76 [0.61-0.95] death Liu -162% 2.62 [0.11-60.6] ICU 1/26 0/16 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Zheng -100% 2.00 [1.23-3.23] death/hosp. 61/2,689 34/3,331 OT1 Evans 51% 0.49 [0.29-0.83] death/hosp. 359 (n) 4,973 (n) Goodwin -110% 2.10 [0.19-22.9] death 1/80 2/336 Butt -9% 1.09 [0.73-1.63] death/hosp. 48/1,459 44/1,459 Fung 4% 0.96 [0.93-0.99] PASC population-based cohort LONG COVID DAWN Tare (RCT) -83% 1.83 [0.69-4.82] no recov. 4/7 5/16 Cheng 15% 0.85 [0.77-0.95] death 4,146 (n) 5,792 (n) Standing (RCT) -103% 2.03 [0.52-7.94] viral+ 6/117 3/119 Razia -272% 3.72 [0.35-39.4] death 2/29 1/54 Yen 18% 0.82 [0.50-1.33] death 250 (n) 1,946 (n) Tau2 = 0.06, I2 = 76.1%, p = 0.032 Early treatment 15% 0.85 [0.73-0.99] 235/28,855 300/37,676 15% lower risk MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Improvement, RR [CI] Treatment Control Wan 11% 0.89 [0.81-0.98] death 704/6,153 2,541/17,283 Wan 13% 0.87 [0.81-0.93] death 2,700 (n) 13,795 (n) Özdemir -50% 1.50 [0.27-8.49] death 3/39 2/39 Lv -53% 1.53 [0.83-2.83] death 12/67 30/257 Lai 10% 0.90 [0.83-0.97] death 4,975 (n) 8,667 (n) Tau2 = 0.00, I2 = 13.3%, p < 0.0001 Late treatment 11% 0.89 [0.84-0.93] 730/14,150 2,574/40,116 11% lower risk MOVe-AHEAD Alpizar (DB RCT) 24% 0.76 [0.57-1.01] symp. case 78/763 103/764 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.049 Prophylaxis 24% 0.76 [0.57-1.01] 78/763 103/764 24% lower risk All studies 14% 0.86 [0.79-0.94] 1,043/43,768 2,977/78,556 14% lower risk 34 molnupiravir COVID-19 peer reviewed studies c19 earlyDecember 2024 Tau2 = 0.02, I2 = 73.0%, p = 0.00089 Effect extraction pre-specified (most serious outcome) 1 OT: comparison with other treatment Favors molnupiravir Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Fischer (RCT) 65% 0.35 [0.01-8.33] death 0/55 1/62 Fischer (RCT) 67% 0.33 [0.01-8.03] death 0/62 1/62 Fischer (RCT) 58% 0.42 [0.02-10.0] death 0/23 1/62 Fischer (RCT) -33% 1.33 [0.14-12.5] hosp. 3/140 1/62 Fischer (RCT) -13% 1.13 [0.07-17.6] hosp. 1/55 1/62 Fischer (RCT) -100% 2.00 [0.19-21.5] hosp. 2/62 1/62 Fischer (RCT) 58% 0.42 [0.02-10.0] hosp. 0/23 1/62 Fischer (RCT) 49% 0.51 [0.22-1.18] viral+ 10/118 9/54 Fischer (RCT) 89% 0.11 [0.01-0.86] viral+ 1/53 9/54 Fischer (RCT) 30% 0.70 [0.25-1.93] viral+ 5/43 9/54 Fischer (RCT) -9% 1.09 [0.37-3.18] viral+ 4/22 9/54 Fischer (RCT) 92% 0.08 [0.01-0.62] viral+ 1/117 6/54 Fischer (RCT) 92% 0.08 [0.01-0.75] viral+ 0/53 6/54 Fischer (RCT) 91% 0.09 [0.01-0.83] viral+ 0/42 6/54 Fischer (RCT) 59% 0.41 [0.05-3.20] viral+ 1/22 6/54 Fischer (RCT) 30% 0.70 [0.37-1.36] viral+ 19/137 12/61 Fischer (RCT) 62% 0.38 [0.13-1.12] viral+ 4/53 12/61 Fischer (RCT) -8% 1.08 [0.54-2.18] viral+ 13/61 12/61 Fischer (RCT) 56% 0.44 [0.11-1.83] viral+ 2/23 12/61 Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Hetero (RCT) 33% 0.67 [0.54-0.82] recov. time 371 (n) 370 (n) Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Khoo (RCT) -100% 2.00 [0.28-14.2] no recov. 4/12 1/6 Khoo (RCT) -100% 2.00 [0.90-4.43] no recov. 4/4 3/6 Khoo (RCT) 0% 1.00 [0.28-3.54] no recov. 2/4 3/6 Khoo (RCT) 0% 1.00 [0.28-3.54] no recov. 2/4 3/6 Khoo (RCT) -50% 1.50 [0.13-17.7] no recov. 1/4 1/6 Khoo (RCT) -200% 3.00 [0.39-23.1] no recov. 2/4 1/6 Khoo (RCT) -50% 1.50 [0.13-17.7] no recov. 1/4 1/6 MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 MOVe-OUT Jayk Ber.. (DB RCT) 30% 0.70 [0.48-1.00] death/hosp. 48/709 68/699 MOVe-OUT Jayk Ber.. (DB RCT) 94% 0.06 [0.00-0.97] death/hosp. 0/37 9/47 MOVe-OUT Jayk Ber.. (DB RCT) 50% 0.50 [0.20-1.26] death/hosp. 6/75 13/82 MOVe-OUT Jayk Ber.. (DB RCT) 24% 0.76 [0.42-1.38] death/hosp. 18/237 22/221 MOVe-OUT Jayk Ber.. (DB RCT) 42% 0.58 [0.20-1.68] death/hosp. 5/47 7/38 MOVe-OUT Jayk Ber.. (DB RCT) 15% 0.85 [0.75-0.98] recovery 709 (n) 699 (n) MOVe-OUT Jayk Ber.. (DB RCT) 19% 0.81 [0.71-0.92] recovery 709 (n) 699 (n) MOVe-OUT Jayk Ber.. (DB RCT) 15% 0.85 [0.75-0.97] recovery 709 (n) 699 (n) MOVe-OUT Jayk Ber.. (DB RCT) 14% 0.86 [0.76-0.97] recovery 709 (n) 699 (n) MOVe-OUT Jayk Ber.. (DB RCT) 4% 0.96 [0.90-1.02] viral load 518 (n) 510 (n) MOVe-OUT Jayk Ber.. (DB RCT) -2% 1.02 [0.97-1.08] viral load 516 (n) 513 (n) MOVe-OUT Jayk Ber.. (DB RCT) 1% 0.99 [0.93-1.05] viral load 515 (n) 506 (n) MOVe-OUT Jayk Ber.. (DB RCT) 13% 0.87 [0.79-0.95] viral load 558 (n) 547 (n) MOVe-OUT Jayk Ber.. (DB RCT) 17% 0.83 [0.71-0.97] viral load 570 (n) 570 (n) Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Tippabhotla (RCT) 46% 0.54 [0.41-0.71] no improv. 67/610 125/610 Tippabhotla (RCT) 52% 0.48 [0.42-0.54] no improv. 199/610 417/610 Tippabhotla (RCT) 25% 0.75 [0.71-0.79] no improv. 433/610 576/610 Tippabhotla (RCT) 59% 0.41 [0.29-0.57] viral+ 42/610 103/610 Tippabhotla (RCT) 81% 0.19 [0.15-0.24] viral+ 62/610 327/610 Tippabhotla (RCT) 78% 0.22 [0.19-0.27] viral+ 113/610 505/610 Wong (PSM) 52% 0.48 [0.40-0.59] death 1,856 (n) 1,856 (n) Wong (PSM) 58% 0.42 [0.17-1.01] ventilation 1,856 (n) 1,856 (n) Wong (PSM) 40% 0.60 [0.52-0.69] progression 1,856 (n) 1,856 (n) Wong (PSM) 6% 0.94 [0.89-1.00] hosp. time 1,856 (n) 1,856 (n) Wong (PSM) 28% 0.72 [0.61-0.87] viral+ 1,856 (n) 1,856 (n) Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Yip (PSW) -17% 1.17 [0.99-1.39] hosp. Zou (RCT) 29% 0.71 [0.28-1.85] recov. time 77 (n) 31 (n) Zou (RCT) 10% 0.90 [0.83-0.97] viral time 76 (n) 31 (n) Zou (RCT) 51% 0.49 [0.28-0.84] viral+ 18/76 15/31 Zou (RCT) 37% 0.63 [0.51-0.78] viral+ 45/76 29/31 Zou (RCT) 18% 0.82 [0.73-0.92] viral+ 62/76 31/31 Flisiak 39% 0.61 [0.38-0.97] death 20/203 63/387 Flisiak 5% 0.95 [0.39-2.32] ventilation 7/203 14/387 Flisiak -1% 1.01 [0.71-1.43] hosp. time 203 (n) 387 (n) AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 AGILE CST-2 Khoo (DB RCT) 89% 0.11 [0.01-2.03] hosp. 0/90 4/90 AGILE CST-2 Khoo (DB RCT) -12% 1.12 [0.71-1.79] no recov. 27/90 24/90 AGILE CST-2 Khoo (DB RCT) 23% 0.77 [0.58-1.09] viral+ 90 (n) 90 (n) Kneidinger -15% 1.15 [0.56-2.37] severe case 8/46 26/172 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] death 22/2,661 27/2,661 Najjar-Deb.. (PSM) 17% 0.83 [0.57-1.21] progression 50/2,661 60/2,661 Najjar-Deb.. (PSM) 25% 0.75 [0.51-1.12] severe case 43/2,661 57/2,661 Arbel 65+ 74% 0.26 [0.10-0.73] death 4/845 137/12,724 Arbel 65+ -1182% 12.82 [3.41-48.2] death 4/224 7/6,075 Arbel 65+ 45% 0.55 [0.34-0.88] hosp. 18/845 513/12,724 Arbel 65+ -80% 1.80 [0.86-3.77] hosp. 8/224 97/6,075 Arbel 40-64 -1182% 12.82 [3.41-48.2] death 4/224 7/6,075 Arbel 40-64 -80% 1.80 [0.86-3.77] hosp. 8/224 97/6,075 Suzuki (PSM) -100% 2.00 [0.34-11.9] death 2/230 3/690 Suzuki (PSM) 57% 0.43 [0.02-10.5] ventilation 0/230 1/690 Suzuki (PSM) 53% 0.47 [0.22-0.98] progression 9/230 58/690 Brown -101% 2.01 [0.43-9.38] hosp. 8/442 2/222 PANORAMIC Butler (RCT) -27% 1.27 [0.65-2.48] death 20/11,778 15/11,230 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] death 3/12,529 5/12,525 PANORAMIC Butler (RCT) -6% 1.06 [0.81-1.41] death/hosp. 105/12,529 98/12,525 PANORAMIC Butler (RCT) -7% 1.07 [0.81-1.41] hosp. 103/12,529 96/12,525 PANORAMIC Butler (RCT) 2% 0.98 [0.94-1.01] transmission 3,887/10,803 3,873/10,548 PANORAMIC Butler (RCT) 22% 0.78 [0.75-0.81] no recov. 3,856/12,403 4,838/12,140 PANORAMIC Butler (RCT) 19% 0.81 [0.78-0.83] recov. time 12,403 (n) 12,140 (n) PANORAMIC Butler (RCT) 30% 0.70 [0.67-0.73] no recov. 2,675/12,403 3,766/12,140 PANORAMIC Butler (RCT) 26% 0.74 [0.71-0.76] recov. time 12,403 (n) 12,140 (n) PANORAMIC Butler (RCT) -95% 1.95 [1.15-3.31] viral load 21 (n) 11 (n) PANORAMIC Butler (RCT) 92% 0.08 [0.05-0.14] viral load 33 (n) 26 (n) Wong (PSM) 24% 0.76 [0.61-0.95] death Wong (PSM) 60% 0.40 [0.19-0.84] ventilation Wong (PSM) 26% 0.74 [0.45-1.21] ICU Wong (PSM) 2% 0.98 [0.89-1.06] hosp. Liu -162% 2.62 [0.11-60.6] ICU 1/26 0/16 Liu 8% 0.92 [0.17-4.94] progression 3/26 2/16 Liu 18% 0.82 [0.63-1.06] hosp. time 26 (n) 16 (n) Liu 21% 0.79 [0.59-1.05] viral time 26 (n) 16 (n) Liu -23% 1.23 [0.12-12.5] viral+ 2/26 1/16 Liu 28% 0.72 [0.29-1.76] viral+ 7/26 6/16 Liu 38% 0.62 [0.41-0.92] viral+ 14/26 14/16 Liu 18% 0.82 [0.64-1.05] viral+ 20/26 15/16 Liu 12% 0.88 [0.75-1.05] viral+ 23/26 16/16 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Sinha (RCT) 53% 0.47 [0.26-0.85] no improv. 16/608 34/610 Sinha (RCT) 48% 0.52 [0.42-0.63] viral load 608 (n) 610 (n) Zheng -100% 2.00 [1.23-3.23] death/hosp. 61/2,689 34/3,331 OT1 Zheng -85% 1.85 [1.14-3.03] death/hosp. 55/2,689 32/3,331 OT1 Bajema (PSM) 18% 0.82 [0.52-1.29] death 24/897 29.0/897 Bajema (PSM) 49% 0.51 [0.20-1.27] death 7/897 13.8/897 Bajema (PSM) 17% 0.83 [0.17-4.12] ventilation 3/897 3.6/897 Bajema (PSM) 1% 0.99 [0.41-2.37] ICU 10/897 10.1/897 Bajema (PSM) -30% 1.30 [1.01-1.68] hosp. 162/897 124.3/897 Bajema (PSM) 9% 0.91 [0.59-1.41] hosp. 37/897 40.5/897 Inaba 58% 0.42 [0.02-10.1] death 0/84 1/210 Inaba -127% 2.27 [0.60-7.25] death/hosp. 5/84 8/210 Inaba -127% 2.27 [0.60-7.25] hosp. 5/84 8/210 Zheng (PSW) -285% 3.85 [1.54-10.0] death/hosp. 11/802 33/4,836 OT1 Evans 51% 0.49 [0.29-0.83] death/hosp. 359 (n) 4,973 (n) Goodwin -110% 2.10 [0.19-22.9] death 1/80 2/336 Goodwin 58% 0.42 [0.05-3.23] hosp. 1/80 10/336 Goodwin 53% 0.47 [0.11-1.97] hosp. 2/80 18/336 Tazare -9% 1.09 [0.93-1.27] death/hosp. Butt -9% 1.09 [0.73-1.63] death/hosp. 48/1,459 44/1,459 Fung 4% 0.96 [0.93-0.99] PASC population-based cohort LONG COVID Fung 8% 0.92 [0.90-0.94] PASC population-based cohort LONG COVID DAWN Tare (RCT) -83% 1.83 [0.69-4.82] no recov. 4/7 5/16 DAWN Tare (RCT) 0% 1.00 [0.61-1.63] no recov. 6/8 12/16 Cheng 15% 0.85 [0.77-0.95] death 4,146 (n) 5,792 (n) Cheng -0% 1.00 [0.76-1.33] oxygen 4,146 (n) 5,792 (n) Cheng 12% 0.88 [0.59-1.30] ICU 4,146 (n) 5,792 (n) Standing (RCT) -103% 2.03 [0.52-7.94] viral+ 6/117 3/119 Standing (RCT) 31% 0.69 [0.44-1.07] viral+ 26/249 52/343 Razia -272% 3.72 [0.35-39.4] death 2/29 1/54 Razia -86% 1.86 [0.12-28.7] ventilation 1/29 1/54 Razia -86% 1.86 [0.28-12.5] ICU 2/29 2/54 Razia 28% 0.72 [0.28-1.81] hosp. 5/29 13/54 Yen 18% 0.82 [0.50-1.33] death 250 (n) 1,946 (n) SAVALO Gentile (PSM) 4% 0.96 [0.70-1.31] death case control SAVALO Gentile (PSM) 26% 0.74 [0.13-4.18] hosp. case control SAVALO Gentile (PSM) 65% 0.35 [0.15-0.81] progression case control 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING2 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING2 MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 MOVe-IN Arribas (DB RCT) -217% 3.17 [0.34-29.8] death 3/71 1/75 MOVe-IN Arribas (DB RCT) -317% 4.17 [0.48-36.4] death 4/72 1/75 MOVe-IN Arribas (DB RCT) -311% 4.11 [0.47-35.9] death 4/73 1/75 MOVe-IN Arribas (DB RCT) 1% 0.99 [0.68-1.45] no recov. 72 (n) 75 (n) MOVe-IN Arribas (DB RCT) 12% 0.88 [0.61-1.28] no recov. 73 (n) 75 (n) MOVe-IN Arribas (DB RCT) -1% 1.01 [0.69-1.47] no recov. 73 (n) 75 (n) MOVe-IN Arribas (DB RCT) 12% 0.88 [0.62-1.25] viral+ 26/52 34/60 MOVe-IN Arribas (DB RCT) -2% 1.02 [0.74-1.41] viral+ 29/50 34/60 MOVe-IN Arribas (DB RCT) 21% 0.79 [0.56-1.13] viral+ 27/60 34/60 MOVe-IN Arribas (DB RCT) 8% 0.92 [0.41-2.08] viral+ 9/53 10/54 MOVe-IN Arribas (DB RCT) -48% 1.48 [0.72-3.03] viral+ 14/51 10/54 MOVe-IN Arribas (DB RCT) 21% 0.79 [0.34-1.84] viral+ 8/55 10/54 Wan 11% 0.89 [0.81-0.98] death 704/6,153 2,541/17,283 Wan 1% 0.99 [0.93-1.05] hosp. 2,298/6,153 2,541/17,283 Wan -4% 1.04 [0.98-1.10] progression 2,300/6,153 2,541/17,283 Wan 13% 0.87 [0.81-0.93] death 2,700 (n) 13,795 (n) Wan -7% 1.07 [0.89-1.30] ventilation 2,700 (n) 13,795 (n) Wan -2% 1.02 [0.76-1.36] ICU 2,700 (n) 13,795 (n) Özdemir -50% 1.50 [0.27-8.49] death 3/39 2/39 Özdemir 0% 1.00 [0.15-6.75] ICU 2/39 2/39 RECOVERY Horby (RCT) -11% 1.11 [0.79-1.58] death 57/445 55/478 RECOVERY Horby (RCT) 7% 0.93 [0.68-1.28] death 74/445 79/478 RECOVERY Horby (RCT) -43% 1.43 [0.50-4.08] ventilation 8/445 6/476 RECOVERY Horby (RCT) -9% 1.09 [0.88-1.35] no disch. 126/445 124/478 RECOVERY Horby (RCT) 12% 0.88 [0.85-0.91] viral load 445 (n) 478 (n) Lv -53% 1.53 [0.83-2.83] death 12/67 30/257 Lai 10% 0.90 [0.83-0.97] death 4,975 (n) 8,667 (n) MOVe-AHEAD Alpizar (DB RCT) 24% 0.76 [0.57-1.01] symp. case 78/763 103/764 Molnupiravir COVID-19 outcomes c19 earlyDecember 2024 1 OT: comparison with other treatment 2 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
